title: Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.
abstract: We report six cases of Pneumocystis jirovecii pneumonia (PCP) verified by immunoflourescence/polymerase chain reaction of bronchoalveolar fluid among 46 lymphoma patients (13%) who received rituximab-CHOEP-14 at our institution. PCP prophylaxis should be standard management for this group of patients and also considered for patients treated with rituximab-CHOP-14, CHOP-14 or CHOEP-14.
authors.forename: Arne
authors.initials: A
authors.lastname: Kolstad
authors.forename: Harald
authors.initials: H
authors.lastname: Holte
authors.forename: Alexander
authors.initials: A
authors.lastname: Fosså
authors.forename: Grete Fossum
authors.initials: GF
authors.lastname: Lauritzsen
authors.forename: Peter
authors.initials: P
authors.lastname: Gaustad
authors.forename: Dag
authors.initials: D
authors.lastname: Torfoss
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001992:Bronchoalveolar Lavage Fluid; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy; D008856:Microscopy, Fluorescence; D008875:Middle Aged; D011010:Pneumocystis / Q000378:metabolism*; D011020:Pneumonia, Pneumocystis / Q000150:complications* / Q000188:drug therapy; D016133:Polymerase Chain Reaction; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone